Global Lichen Sclerosus Treatment 麻豆原创 Growth (Status and Outlook) 2024-2030

Publication ID:

LPI08253253

Publication Date:

August 19, 2024

Pages:

117

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Lichen sclerosus is a chronic disorder of the skin, affecting the genital and anal areas. However, in some serious cases, they may appear on upper body such as arms and breast regions. According to various studies, lichen sclerosus is most common in females (after menopause), uncommon in adult males, and very rare in children. Lichen sclerosus appears by forming white spots on the affected regions, the spots may be glossy and smooth in appearance, if untreated they develop into bigger patches. In addition, lichen sclerosus may result in red or purple colored bruises, skin becomes more prone to tear, itching and bleeding. The main cause of lichen sclerosus is still unknown, it is believed to be caused by hyper-immunity reactions or by hormonal imbalance. An individual with previous skin destruction around genital or anal region, are more susceptible to develop lichen sclerosus. Corticosteroids are mainly used for the treatment and management of lichen sclerosus. Women with vulva鈥檚 lichen sclerosus are at a high risk of causing vulvar cancer.
The global Lichen Sclerosus Treatment market size is projected to grow from US$ 92 million in 2023 to US$ 126.1 million in 2030; it is expected to grow at a CAGR of 4.6% from 2024 to 2030.
The 鈥淟ichen Sclerosus Treatment Industry Forecast鈥� looks at past sales and reviews total world Lichen Sclerosus Treatment sales in 2023, providing a comprehensive analysis by region and market sector of projected Lichen Sclerosus Treatment sales for 2024 through 2030. With Lichen Sclerosus Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Lichen Sclerosus Treatment industry.
This Insight Report provides a comprehensive analysis of the global Lichen Sclerosus Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Lichen Sclerosus Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Lichen Sclerosus Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Lichen Sclerosus Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Lichen Sclerosus Treatment.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of Lichen Sclerosus Treatment market by product type, application, key players and key regions and countries.
Segmentation by type
Topical
Oral
Injection
Others
Segmentation by application
Hospital Pharmacies
Clinics
Retail Pharmacies
Online Pharmacies
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
GlaxoSmithKline
Johnson & Johnson
Merck
Pfizer
AstraZeneca
Sandoz AG (Novartis AG)
Sanofi S.A
Bristol-Myers Squibb Company
Bausch Health
Zylera Pharmaceuticals

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Lichen Sclerosus Treatment 麻豆原创 Size 2019-2030
2.1.2 Lichen Sclerosus Treatment 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Lichen Sclerosus Treatment Segment by Type
2.2.1 Topical
2.2.2 Oral
2.2.3 Injection
2.2.4 Others
2.3 Lichen Sclerosus Treatment 麻豆原创 Size by Type
2.3.1 Lichen Sclerosus Treatment 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Lichen Sclerosus Treatment 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 Lichen Sclerosus Treatment Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Clinics
2.4.3 Retail Pharmacies
2.4.4 Online Pharmacies
2.4.5 Others
2.5 Lichen Sclerosus Treatment 麻豆原创 Size by Application
2.5.1 Lichen Sclerosus Treatment 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Lichen Sclerosus Treatment 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 Lichen Sclerosus Treatment 麻豆原创 Size by Player
3.1 Lichen Sclerosus Treatment 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global Lichen Sclerosus Treatment Revenue by Players (2019-2024)
3.1.2 Global Lichen Sclerosus Treatment Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Lichen Sclerosus Treatment Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Lichen Sclerosus Treatment by Regions
4.1 Lichen Sclerosus Treatment 麻豆原创 Size by Regions (2019-2024)
4.2 Americas Lichen Sclerosus Treatment 麻豆原创 Size Growth (2019-2024)
4.3 APAC Lichen Sclerosus Treatment 麻豆原创 Size Growth (2019-2024)
4.4 Europe Lichen Sclerosus Treatment 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa Lichen Sclerosus Treatment 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas Lichen Sclerosus Treatment 麻豆原创 Size by Country (2019-2024)
5.2 Americas Lichen Sclerosus Treatment 麻豆原创 Size by Type (2019-2024)
5.3 Americas Lichen Sclerosus Treatment 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Lichen Sclerosus Treatment 麻豆原创 Size by Region (2019-2024)
6.2 APAC Lichen Sclerosus Treatment 麻豆原创 Size by Type (2019-2024)
6.3 APAC Lichen Sclerosus Treatment 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Lichen Sclerosus Treatment by Country (2019-2024)
7.2 Europe Lichen Sclerosus Treatment 麻豆原创 Size by Type (2019-2024)
7.3 Europe Lichen Sclerosus Treatment 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Lichen Sclerosus Treatment by Region (2019-2024)
8.2 Middle East & Africa Lichen Sclerosus Treatment 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa Lichen Sclerosus Treatment 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Lichen Sclerosus Treatment 麻豆原创 Forecast
10.1 Global Lichen Sclerosus Treatment Forecast by Regions (2025-2030)
10.1.1 Global Lichen Sclerosus Treatment Forecast by Regions (2025-2030)
10.1.2 Americas Lichen Sclerosus Treatment Forecast
10.1.3 APAC Lichen Sclerosus Treatment Forecast
10.1.4 Europe Lichen Sclerosus Treatment Forecast
10.1.5 Middle East & Africa Lichen Sclerosus Treatment Forecast
10.2 Americas Lichen Sclerosus Treatment Forecast by Country (2025-2030)
10.2.1 United States Lichen Sclerosus Treatment 麻豆原创 Forecast
10.2.2 Canada Lichen Sclerosus Treatment 麻豆原创 Forecast
10.2.3 Mexico Lichen Sclerosus Treatment 麻豆原创 Forecast
10.2.4 Brazil Lichen Sclerosus Treatment 麻豆原创 Forecast
10.3 APAC Lichen Sclerosus Treatment Forecast by Region (2025-2030)
10.3.1 China Lichen Sclerosus Treatment 麻豆原创 Forecast
10.3.2 Japan Lichen Sclerosus Treatment 麻豆原创 Forecast
10.3.3 Korea Lichen Sclerosus Treatment 麻豆原创 Forecast
10.3.4 Southeast Asia Lichen Sclerosus Treatment 麻豆原创 Forecast
10.3.5 India Lichen Sclerosus Treatment 麻豆原创 Forecast
10.3.6 Australia Lichen Sclerosus Treatment 麻豆原创 Forecast
10.4 Europe Lichen Sclerosus Treatment Forecast by Country (2025-2030)
10.4.1 Germany Lichen Sclerosus Treatment 麻豆原创 Forecast
10.4.2 France Lichen Sclerosus Treatment 麻豆原创 Forecast
10.4.3 UK Lichen Sclerosus Treatment 麻豆原创 Forecast
10.4.4 Italy Lichen Sclerosus Treatment 麻豆原创 Forecast
10.4.5 Russia Lichen Sclerosus Treatment 麻豆原创 Forecast
10.5 Middle East & Africa Lichen Sclerosus Treatment Forecast by Region (2025-2030)
10.5.1 Egypt Lichen Sclerosus Treatment 麻豆原创 Forecast
10.5.2 South Africa Lichen Sclerosus Treatment 麻豆原创 Forecast
10.5.3 Israel Lichen Sclerosus Treatment 麻豆原创 Forecast
10.5.4 Turkey Lichen Sclerosus Treatment 麻豆原创 Forecast
10.5.5 GCC Countries Lichen Sclerosus Treatment 麻豆原创 Forecast
10.6 Global Lichen Sclerosus Treatment Forecast by Type (2025-2030)
10.7 Global Lichen Sclerosus Treatment Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Information
11.1.2 GlaxoSmithKline Lichen Sclerosus Treatment Product Offered
11.1.3 GlaxoSmithKline Lichen Sclerosus Treatment Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 GlaxoSmithKline Main Business Overview
11.1.5 GlaxoSmithKline Latest Developments
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Information
11.2.2 Johnson & Johnson Lichen Sclerosus Treatment Product Offered
11.2.3 Johnson & Johnson Lichen Sclerosus Treatment Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Johnson & Johnson Main Business Overview
11.2.5 Johnson & Johnson Latest Developments
11.3 Merck
11.3.1 Merck Company Information
11.3.2 Merck Lichen Sclerosus Treatment Product Offered
11.3.3 Merck Lichen Sclerosus Treatment Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Merck Main Business Overview
11.3.5 Merck Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Lichen Sclerosus Treatment Product Offered
11.4.3 Pfizer Lichen Sclerosus Treatment Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 AstraZeneca
11.5.1 AstraZeneca Company Information
11.5.2 AstraZeneca Lichen Sclerosus Treatment Product Offered
11.5.3 AstraZeneca Lichen Sclerosus Treatment Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 AstraZeneca Main Business Overview
11.5.5 AstraZeneca Latest Developments
11.6 Sandoz AG (Novartis AG)
11.6.1 Sandoz AG (Novartis AG) Company Information
11.6.2 Sandoz AG (Novartis AG) Lichen Sclerosus Treatment Product Offered
11.6.3 Sandoz AG (Novartis AG) Lichen Sclerosus Treatment Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Sandoz AG (Novartis AG) Main Business Overview
11.6.5 Sandoz AG (Novartis AG) Latest Developments
11.7 Sanofi S.A
11.7.1 Sanofi S.A Company Information
11.7.2 Sanofi S.A Lichen Sclerosus Treatment Product Offered
11.7.3 Sanofi S.A Lichen Sclerosus Treatment Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 Sanofi S.A Main Business Overview
11.7.5 Sanofi S.A Latest Developments
11.8 Bristol-Myers Squibb Company
11.8.1 Bristol-Myers Squibb Company Company Information
11.8.2 Bristol-Myers Squibb Company Lichen Sclerosus Treatment Product Offered
11.8.3 Bristol-Myers Squibb Company Lichen Sclerosus Treatment Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Bristol-Myers Squibb Company Main Business Overview
11.8.5 Bristol-Myers Squibb Company Latest Developments
11.9 Bausch Health
11.9.1 Bausch Health Company Information
11.9.2 Bausch Health Lichen Sclerosus Treatment Product Offered
11.9.3 Bausch Health Lichen Sclerosus Treatment Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 Bausch Health Main Business Overview
11.9.5 Bausch Health Latest Developments
11.10 Zylera Pharmaceuticals
11.10.1 Zylera Pharmaceuticals Company Information
11.10.2 Zylera Pharmaceuticals Lichen Sclerosus Treatment Product Offered
11.10.3 Zylera Pharmaceuticals Lichen Sclerosus Treatment Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Zylera Pharmaceuticals Main Business Overview
11.10.5 Zylera Pharmaceuticals Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.